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Abstract
Background: Venous thromboembolism (VTE) is a common, life- threatening compli-
cation of COVID- 19 infection. COVID- 19 risk- prediction models include a history of 
VTE. However, it is unclear whether remote history (>9 years previously) of VTE also 
confers increased risk of COVID- 19.
Objectives: To investigate possible association between VTE and COVID- 19 severity, 
independent of other risk factors.
Methods: Cohort study of UK Biobank participants recruited between 2006 and 
2010. Baseline data, including history of VTE, were linked to COVID- 19 test results, 
COVID- 19- related hospital admissions, and COVID- 19 deaths. The risk of COVID- 19 
hospitalization or death was compared for participants with a remote history VTE ver-
sus without. Poisson regression models were run univariately then adjusted stepwise 
for sociodemographic, lifestyle, and comorbid covariates.
Results: After adjustment for sociodemographic and lifestyle confounders and co-
morbid conditions, remote history of VTE was associated with nonfatal community 
(RR 1.61, 95% CI 1.02– 2.54, p = .039), nonfatal hospitalized (RR 1.52, 95% CI 1.06– 
2.17, p = .024) and severe (hospitalized or fatal) (RR 1.40, 95% CI 1.04– 1.89, p = .025) 
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1  |  INTRODUC TION
Venous thromboembolism (VTE), which includes pulmonary em-
bolism and deep vein thrombosis, is a common and a serious com-
plication of severe COVID- 19 infection.1 Despite anticoagulant 
thromboprophylaxis being recommended and empirically used for 
all hospitalized COVID- 19 patients,2 larger studies suggest that 7% 
to 8% still develop VTE, as do 46% of those admitted to intensive 
care units.3 Many randomized controlled trials are now evaluating 
antithrombotic agents and intensities of anticoagulation for patients 
hospitalized with COVID- 19.4 Recent publications cast uncertainty 
about the best course of action but potentially patients who are 
less sick might benefit from more intense anticoagulation but for 
patients with severe disease it may be too late.5 The potential ben-
efits of more intense anticoagulation must be weighed against the 
risk of bleeding, which is also increased with COVID- 19 infection.6,7 
Following discharge from hospital, there is an elevated risk of both 
thrombosis and hemorrhage, so universal postdischarge anticoagu-
lation or antiplatelet therapy needs further evaluation, too.8
Risk stratification for VTE complications in COVID- 19 patients 
is needed to improve the risk- benefit ratio of targeted anticoagula-
tion strategies.9 In the most recent QCovid predictive score (https://
qcovid.org/),10 history of VTE was identified, and included as a risk 
factor for both COVID- 19 severity and VTE complications after 
COVID- 19 infection, but no differentiation was made between re-
mote and recent history of VTE. It is uncertain whether a remote 
history of VTE is a risk factor for severe COVID- 19 infection. We 
used UK Biobank data, collected >9 years before the COVID- 19 pan-
demic, to address this question.
2  |  METHODS
2.1  |  Exposure and outcomes
UK Biobank, a general population cohort, recruited participants 
aged 37 to 73 years between 2006 and 2010. At enrollment, par-
ticipants had physical measurements taken and provided informa-
tion by completing a touch- screen questionnaire, which included 
questions about medical history, including self- report of physician 
diagnosis of deep vein thrombosis or pulmonary embolism,11 here 
combined as VTE. COVID- 19 test results of participants living in 
England and hospital admissions were obtained from Public Health 
England12 and COVID- 19 deaths from death certificates, between 
16 March 2020 and 22 July 2020. COVID- 19 infection was defined 
as more than one COVID- 19- positive polymerase chain reaction test 
or COVID- 19 stated on death certificate and categorized into: non-
fatal community, nonfatal hospitalized, and died from COVID- 19 (in 
hospital or in community). Severe COVID- 19 was defined as hospi-
talization for or death from COVID- 19 and ascertained by combining 
the latter two categories. These data were linked to the UK Biobank 
participants’ data collected at enrollment.
2.2  |  Covariates
Sociodemographic factors included age (continuous), sex (male/fe-
male), Townsend deprivation index (continuous), ethnicity (White, 
mixed, South Asian, Black, Chinese, any other). Lifestyle factors in-
cluded body mass index (BMI) calculated from weight/height2 and 
categorized into underweight <18.5 kg/m2, normal weight 18.5 to 
24.9 kg/m2, overweight 25.0 to 29.9 kg/m2, and obese ≥30.0 kg/m2; 
smoking (never, past. or current smoker); physical activity, derived 
from the questions about moderate and vigorous physical activ-
ity in the International Physical Activity Questionnaire, converted 
into metabolic equivalents (METs) and dichotomized into inactive 
(<600 MET min/week) and active (>600 MET min/week)13; and fre-
quency of alcohol consumption (never, special occasions only, one 
to three times a month, once or twice a week, three or four times a 
week, and daily or almost daily). Self- report of physician diagnoses 
included cardiovascular disease (myocardial infarction, heart failure, 
COVID- 19. Associations with remote history of VTE were stronger among men (severe 
COVID- 19: RR 1.68, 95% CI 1.14– 2.42, p = .009) than for women (severe COVID- 19: 
RR 1.07, 95% CI 0.66– 1.74, p = .786).
Conclusion: Our findings support inclusion of remote history of VTE in COVID- 19 
risk- prediction scores, and consideration of sex- specific risk scores.
K E Y W O R D S
COVID- 19 severity, DVT, PE, SARS- CoV2 infection, venous thromboembolism
Essentials
• Venous thromboembolism (VTE) is a common complica-
tion of severe COVID- 19 infection.
• COVID- 19 prediction scores include history of VTE but 
it is unknown if remote history is relevant.
• UK Biobank data show an independent association be-
tween remote history of VTE and severe COVID- 19.
• Our findings support inclusion of remote history of VTE 
in COVID- 19 risk- prediction scores.
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angina, stroke, transient ischemic attack, atrial fibrillation/flutter, 
valve disease) and diabetes mellitus (type 1 and type 2). Women 
were categorized as currently receiving exogenous estrogens (com-
bined oral contraceptive pill or hormone replacement therapy) or 
not. Medication included any antiplatelet and anticoagulant medica-
tion taken regularly at the time of recruitment.
2.3  |  Statistical analyses
The characteristics of the study population, broken down by history 
of VTE or not, were summarized using the median and interquar-
tile range for continuous variables and frequencies and propor-
tions for categorical variables. Poisson regression models were run 
univariately, then adjusted for sociodemographic factors only (sex, 
age, deprivation, ethnicity), then also lifestyle factors (BMI, smok-
ing, physical activity, and alcohol consumption frequency), and then 
also prevalent cardiovascular disease and diabetes at baseline. For 
women, use of exogenous estrogens (combined oral contraceptive 
pill/hormone replacement therapy or neither) at baseline was an 
additional covariate in the final adjusted model. Subgroup analyses 
were performed by sex and by antiplatelet and anticoagulant medi-
cation status at baseline. Participants with missing data on history 
of VTE were excluded from this study and participants with miss-
ing data for any covariates (3.3%) were excluded from the statistical 
analyses. Analyses were performed using STATA 14 (Stata).
3  |  RESULTS AND DISCUSSION
After excluding participants who withdrew from UK Biobank 
(N = 120), those who were recruited in assessment centers outside 
of England (N = 56 664), those who died before March 2020 when 
COVID- 19 testing commenced (N = 26 242), and those with missing 
information on history of VTE (N = 107 320), 312 378 participants 
were eligible for inclusion, of whom 10 034 (3.2%) reported a history 
of VTE at baseline. Overall, 1402 (0.45%) participants were recorded 
as being infected with COVID- 19 over the study period: 421 (0.14%) 
were nonfatal community cases, 646 (0.21%) were nonfatal hospi-
talized cases, and 335 (0.11%) died from COVID- 19. Therefore, 981 
(0.31%) developed severe COVID- 19 defined as requiring hospitali-
zation or death.
Participants who reported a history of VTE at baseline were 
older, more deprived, and more likely to be female and white 
(Table 1). They were less physically active, more likely to be obese 
and current or past smokers, more likely to have comorbid diabetes 
and cardiovascular disease and be on regular antiplatelet or antico-
agulant therapy, but were less likely to consume alcohol weekly or 
daily (Table 1). Women with a history of VTE were less likely to be 
on exogenous estrogens at recruitment. Those with history of VTE 
at baseline were more likely to have subsequently had COVID- 19 
(0.8% vs 0.4%) and more likely to have had severe COVID- 19 (0.5% 
vs 0.3%).
Univariately, history of VTE was associated with nonfatal com-
munity (RR 1.59, 95% CI 1.02– 2.46, p = .039), nonfatal hospitalized 
(RR 1.94, 95% CI 1.40– 2.68, p < .001), and severe (RR 1.76, 95% 
CI 1.34– 2.31, p < .001) COVID- 19. The association with death from 
COVID- 19 was not significant (RR 1.42, 95% CI 0.84– 2.38, p = .187). 
After adjustment for sociodemographic and lifestyle confounders as 
well as comorbid cardiovascular disease, the associations remained 
for nonfatal community (RR 1.61, 95% CI 1.02– 2.54, p = .039), 
nonfatal hospitalized (RR 1.52, 95% CI 1.06– 2.17, p = 0.024), and 
severe (RR 1.40, 95% CI 1.04– 1.89, p = .025) COVID- 19 (Table 2). 
There were significant interactions with sex (nonfatal hospitalized 
COVID- 19 p = .009; severe COVID- 19 p = .010). In subgroup analy-
sis, the associations were stronger for men and not statistically sig-
nificant for women (Table 2).
Participants with a remote history of VTE not taking antithrom-
botic therapy at baseline had a higher risk of nonfatal hospitalized 
(RR 2.05, 95% CI 1.29– 3.24, p = .002) and severe COVID- 19 (RR 
1.84, 95% CI 1.25– 2.70, p = .002), with similar but nonsignificant 
trends for deaths from (RR 1.46, 95% CI 0.72– 2.96, p = .292) or non-
fatal community COVID- 19 (RR 1.74, 95% CI 0.95– 3.20, p = .075). 
These associations were absent for those with a remote history of 
VTE and on antiplatelet and/or anticoagulant medication at baseline: 
nonfatal hospitalized (RR 1.31, 95% CI 0.71– 2.43, p = .386) and se-
vere COVID- 19 (RR 1.25, 95% CI 0.77– 2.01, p = .369), deaths from 
(RR 1.15, 95% CI 0.53– 2.48, p = .729), or nonfatal community (RR 
0.85, 95% CI 0.30– 2.40, p = .764) COVID- 19.
Remote history of VTE was associated with hospitalized and 
severe COVID- 19 disease, independent of sociodemographic char-
acteristics, lifestyle, and comorbidity. The excess risk of hospital-
ization with COVID- 19 appeared somewhat higher, although the 
confidence intervals overlapped. This might reflect incorrect attri-
bution of the cause of deaths by clinicians for people who died in 
the community; either the relationship to COVID- 19 was missed due 
to lack of testing or deaths from respiratory disease were wrongly 
ascribed to COVID- 19. Interaction tests and subgroup analyses show 
that the association between remote history of VTE and COVID- 19 
hospitalizations was specific to men; with no association in women 
irrespective of their use of exogenous estrogens. Clinical guidelines 
recommend that hormone therapy should be avoided in women with 
a history of VTE.14 Men with a remote history of VTE were more 
likely to have a positive test for COVID- 19 and to be hospitalized or 
die from it. Women and men are presumably at similar risk of getting 
COVID- 19 infection, but men are known to have a higher risk of de-
veloping severe disease. Male sex may amplify the prothrombotic 
effects of COVID- 19 infection and consequently of severe disease.
Also, patients with a remote history of VTE treated with anti-
platelet agents or anticoagulants appeared to be protected from 
developing more severe COVID- 19. This is interesting, because ac-
tivation of hemostatic pathways, in the micro- or macro- circulation, 
may be an important mechanism determining the severity of 
COVID- 19. Antithrombotic prophylaxis with, for instance, a low 
dose of a novel oral anticoagulant and/or aspirin might reduce 
the risks of developing severe COVID- 19.15 In the COMPASS trial, 




N = 302 344
Yes
N = 10 034
Median (IQR) Median (IQR)
Age (years) 59 (51, 64) 61 (54, 65) <.001
Deprivation index −2.1 (−3.6, 0.6) −1.9 (−3.5, 1.0) <.001
N (%) N (%)
Sex
Male 135 520 (44.8) 3899 (38.9) <.001
Female 166 824 (55.2) 6135 (61.1)
Ethnic group
White 283 180 (94.1) 9570 (95.4) <.001
South Asian 6644 (2.2) 128 (1.3)
Black 5427 (1.8) 171 (1.7)
Chinese 858 (0.29) 5 (0.1)
Mixed 1844 (0.6) 59 (0.6)
Any other 2900 (0.96) 70 (0.7)
Smoking status
Current 29 070 (9.7) 1089 (10.9) <.001
Past 108 441 (36.1) 3717 (37.2)
Never 163 213 (54.3) 5175 (51.8)
Body mass index
Underweight 1260 (0.4) 22 (0.2) <.001
Normal weight 88 037 (29.7) 2113 (21.9)
Overweight 127 918 (43.1) 3900 (40.4)
Obese 79 518 (26.8) 3615 (37.5)
Alcohol frequency
Never 25 601 (8.5) 1171 (11.7) <.001
Special occasions only 36 556 (12.1) 1508 (15.1)
1– 3 times/month 34 119 (11.3) 1182 (11.8)
1– 2 times/week 75 930 (25.2) 2377 (23.7)
3– 4 times/week 67 961 (22.5) 1968 (19.6)
Daily or almost daily 61 465 (20.4) 1811 (18.1)
Physically active 159 794 (52.9) 5066 (50.5) <.001
Cardiovascular disease 20 897 (6.9) 1236 (12.3) <.001
Diabetes 19 228 (6.4) 789 (7.9) <.001
Anticoagulants
Yes 2341 (0.9) 1162 (13.7) <.001
No 247 015 (99.1) 7313 (86.3)
Antiplatelets
Yes 48 919 (19.6) 2261 (26.7) <.001
No 200 437 (80.4) 6214 (73.3)
COCP/HRT
Yes 16 950 (10.2) 414 (6.8) <.001
No 148 848 (89.8) 5668 (93.2)
Note: Categorical variables compared by χ2 test; continuous variables compared by Mann- Whitney 
U test.
Abbreviations: COCP, combined oral contraceptive pill; HRT, hormone replacement therapy; IQR, 
interquartile range; VTE, venous thromboembolism.
TA B L E  1  Characteristics of study 
participants by history of venous 
thromboembolism
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patients with stable atherosclerotic vascular disease were ran-
domized to aspirin 100 mg/day alone, aspirin 100 mg/day plus ri-
varoxaban 2.5 mg twice daily, or rivaroxaban 5 mg twice daily. The 
trial was stopped early because of benefit, including reductions 
in stroke, venous thromboembolism, cardiovascular, and all- cause 
mortality among patients assigned combination therapy compared 
with aspirin alone.15 If the sequence of events leading to severe 
COVID- 19 is indeed infection, systemic inflammation, endothelial 
damage, and finally microvascular thrombosis and occlusion in the 
pulmonary, renal, cardiac, and other circulations, then intervention 
before the development of this final step could prevent the most 
serious consequences of COVID- 19. To date, trials of antithrombotic 
agents in late stages of the disease with widespread activation of 
hemostasis have not improved COVID- 19 outcomes (RECOVERY 
trial; www.recov erytr ial.net). This does not preclude the possibility 
that much earlier intervention might prevent progression to more 
severe disease.
The study has several strengths. To our knowledge, this is the 
first study to investigate whether a remote (>9 years previously) his-
tory of VTE is associated with severe COVID- 19 disease. UK Biobank 
is a large, well- characterized general population cohort (10 074 par-
ticipants had a remote history of VTE) and we were able to adjust for 
a wide range of potential confounders and were powered to under-
take subgroup analyses.
There are several limitations to our study. UK Biobank is not 
representative of the general population in terms of sociodemo-
graphic and lifestyle factors; however, estimates of effect size are 
nonetheless generalizable.16 History of VTE and covariates were 
measured at baseline and may have changed over time; however, we 
have focused on remote (>9 years previously) history of VTE. We 
had no data on VTE events or use of antithrombotic/anticoagulant 
medication at the time of infection. In addition, a large number of 
patients was excluded because of missing information on history 
of VTE. Such individuals were younger, from more deprived areas, 
more likely to be non- White, to drink alcohol, but also be more ac-
tive and have lower BMI. It is possible these differences could have 
biased our results.
Finally, ascertainment of COVID- 19 was dependent on the test-
ing strategy in operation at the time. In our report, 70% of cases 
were severe, which is a much higher proportion than expected. It 
is likely that participants with mild or asymptomatic infections did 
not seek medical attention and were therefore not tested and, con-
sequently, were included in the comparison group. This detection 
bias might have diluted the association between remote history of 
VTE and COVID- 19 infection. However, it is unlikely that VTE would 
predispose to being infected with COVID- 19. It is far more likely 
that having a remote history of VTE identifies people who, when 
infected, develop more severe manifestations of the disease.12 Also, 
people with remote history of VTE were more likely also to have 
other cardiovascular problems. It is possible that the threshold for 
admission was lower in these patients, which might have strength-
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4  |  CONCLUSIONS
Our findings support inclusion of any history of VTE, including re-
mote, in the QCovid risk score and other risk scores. They show that 
the risk was specific to men. The lack of an association in women 
needs to be corroborated in other studies but sex- specific risk scores 
should be considered. These findings also support testing antico-
agulants and antiplatelet agents in the prevention of more severe 
COVID- 19 outcomes. Individuals with a history of VTE should be 
considered a potential priority group for vaccination.
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